1. US Department of Health and Human Services . 17 October2014. U.S. Government gain-of-function deliberative process and research funding pause on selected gain-of-function research involving influenza, MERS, and SARS viruses. US Department of Health and Human Services, Washington, DC. https://www.phe.gov/s3/dualuse/documents/gain-of-function.pdf .
2. White House Office of Science and Technology Policy . 9 January2017. Recommended policy guidance for potential pandemic pathogen care and oversight (P3CO). White House Office of Science and Technology Policy, Washington, DC. https://www.whitehouse.gov/blog/2017/01/09/recommended-policy-guidance-potential-pandemic-pathogen-care-and-oversight .
3. Ritterson R Kazmierczak M Isbell M Hulme-Lowe C Lauer E Finnegan M Krem H Cerles A Venugopalan G Handoko R Chu J Fields D Casagrande R . 2016. Supporting an estimate of absolute risk, p 161–164. InRisk and benefit analysis of gain of function research. Final report—April 2016. Gryphon Scientific, LLC, Takoma Park, MD. http://www.gryphonscientific.com/wp-content/uploads/2016/04/Risk-and-Benefit-Analysis-of-Gain-of-Function-Research-Final-Report.pdf .
4. Ritterson R Kazmierczak M Isbell M Hulme-Lowe C Lauer E Finnegan M Krem H Cerles A Venugopalan G Handoko R Chu J Fields D Casagrande R . 2016. Risk and benefit analysis of gain of function research, supplemental information for Chapter 6. Gryphon Scientific, LLC, Takoma Park, MD. http://www.gryphonscientific.com/wp-content/uploads/2015/12/Supporting-Information-Event-Tree-Details-and-Probabilities.pdf .
5. Fort Point Associates, Inc . 2013. BioSquare phase II supplemental final environmental impact report. Fort Point Associates, Inc., Boston, MA.